IBANDRONATE SODIUM
Clinical safety rating: avoid
Contraindicated (not allowed)
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and interfering with the mevalonate pathway, leading to loss of osteoclast activity and induction of apoptosis.
| Metabolism | Not metabolized; eliminated renally via active tubular secretion and glomerular filtration. No known CYP450 involvement. |
| Excretion | Renal excretion of unchanged drug via glomerular filtration and tubular secretion; approximately 50-60% of absorbed dose is excreted unchanged in urine within 24 hours, with cumulative urinary excretion accounting for 50-80% of systemically absorbed dose; non-renal clearance (biliary/fecal) is negligible (<1%). |
| Half-life | Terminal elimination half-life ranges from 10 to 60 hours, with a mean of approximately 37 hours; due to high affinity for bone, the drug is slowly released from bone compartment, resulting in an extended terminal half-life of up to 90-160 hours in bone; clinical context: supports once-monthly oral dosing and once-every-3-months intravenous dosing for osteoporosis. |
| Protein binding | Approximately 84-88% bound to serum proteins, primarily albumin; binding is concentration-independent over therapeutic range (0.1-10 ng/mL). |
| Volume of Distribution | Apparent steady-state volume of distribution is approximately 90 L (1.3 L/kg for a 70 kg individual); extensive distribution into bone (hydroxyapatite), with bone uptake accounting for 40-50% of the dose; large Vd indicates extensive tissue binding, minimal distribution into red blood cells. |
| Bioavailability | Oral: absolute bioavailability is approximately 0.6% under fasting conditions (range 0.4-0.8%); coadministration with food or calcium reduces bioavailability significantly (up to 90% reduction); Intravenous: 100% bioavailability. |
| Onset of Action | Oral: suppression of bone resorption markers (e.g., serum CTX) begins within 1-3 days after a single dose, with maximal effect observed after 7-14 days; Intravenous: rapid onset with reduction in bone resorption markers within 24 hours. |
| Duration of Action | After single oral dose, suppression of bone turnover markers persists for at least 28 days; after intravenous bolus, effect lasts for approximately 3 months; sustained effect is due to long bone retention; clinical notes: supports monthly oral and quarterly IV dosing regimens. |
| Molecular Weight | 359.24 Da (as sodium salt; ibandronic acid: 319.24 Da) |
150 mg orally once monthly for osteoporosis; 3 mg intravenously over 15-30 seconds every 3 months for osteoporosis; 6 mg intravenously over 15-30 minutes for metastatic bone disease (repeat every 3-4 weeks).
| Dosage form | TABLET |
| Renal impairment | CrCl >=30 mL/min: no adjustment. CrCl <30 mL/min: not recommended for oral; IV: 2 mg every 3 months for osteoporosis; for malignancy, reduce dose or extend interval based on CrCl (e.g., CrCl 30-50: 4 mg; CrCl 18-29: 2 mg; <18: not studied). |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). No recommended dose. |
| Geriatric use | No specific dose adjustment based on age alone. Assess renal function and adjust dose accordingly (see renal adjustment). Monitor for renal toxicity, hypocalcemia, and musculoskeletal pain. |
| 1st trimester | Avoid use; animal studies show embryotoxicity and fetal malformations at doses similar to human exposure. Human data limited, but bisphosphonates cross placenta and may accumulate in bone. |
| 2nd trimester | Avoid use; risk of fetal skeletal and renal toxicity. May cause hypocalcemia in neonate if used near term. |
| 3rd trimester | Avoid use; potential for neonatal hypocalcemia and skeletal abnormalities. Use only if benefit outweighs risk. |
Clinical note
Calcium supplements and other oral medications can interfere with absorption Risk of esophageal irritation and osteonecrosis of the jaw.
| Placental transfer | Crosses placenta in animals; human data limited but bisphosphonates are known to cross placenta and accumulate in fetal bone. |
| Breastfeeding | Excretion into human milk unknown. In animal studies, ibandronate is present in milk. Due to potential for bone growth suppression and hypocalcemia in infant, advise against breastfeeding during therapy. |
■ FDA Black Box Warning
None
| Common Effects | Headache Musculoskeletal bone muscle or joint pain Heartburn Diarrhea Indigestion Dizziness Hypercholesterolemia high cholesterol Upper respiratory tract infection Urinary tract infection |
| Serious Effects |
HypocalcemiaSevere renal impairment (CrCl <30 mL/min)Inability to stand or sit upright for at least 60 minutesHypersensitivity to ibandronate or any component
| Precautions | Severe and occasionally incapacitating bone, joint, or muscle pain, Osteonecrosis of the jaw, especially with invasive dental procedures, Atypical femur fractures, Hypocalcemia must be corrected before initiation, Renal impairment (CrCl <30 mL/min is not recommended), Severe renal impairment and dialysis patients |
| Food/Dietary | Oral ibandronate must be taken with plain water only, at least 60 minutes before any food, beverage (other than water), or other medications. Calcium-rich foods, antacids, and mineral supplements can significantly reduce absorption if taken too close; must be separated by at least 60 minutes. Avoid orange juice, coffee, and mineral water as they may interfere. |
Loading safety data…
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal skeletal abnormalities. Second/third trimesters: Potential for fetal hypocalcemia and skeletal effects due to bisphosphonate incorporation into bone matrix. Avoid use in pregnancy unless clearly needed. |
| Fetal Monitoring | Monitor maternal serum calcium, phosphate, magnesium, and renal function. Fetal ultrasound for skeletal development if exposed during pregnancy. Assess neonatal calcium status at birth. |
| Fertility Effects | In animal studies, ovarian enlargement and impaired fertility at high doses. Human data limited; reversible upon discontinuation. |
| Clinical Pearls | Monitor serum creatinine before each dose; avoid use if CrCl <30 mL/min. Adequate calcium and vitamin D intake is essential. Administer intravenously over at least 15 minutes to reduce renal risk. Can cause acute renal failure, especially with pre-existing renal impairment or dehydration. Consider dose adjustment in severe hepatic impairment. May cause osteonecrosis of the jaw, especially in cancer patients; perform dental exam before starting therapy. Hypocalcemia must be corrected prior to initiation. Not recommended for use in pediatric patients. |
| Patient Advice | Take calcium and vitamin D supplements as directed to prevent low calcium levels. · For oral tablets: take with a full glass of plain water at least 60 minutes before first food or drink of the day; do not chew or suck tablet. · For IV infusion: drink plenty of water before and after the infusion to stay hydrated. · Report any jaw pain, swelling, or numbness especially after dental procedures. · Inform your dentist that you are taking this medication before any dental work. · Seek medical attention if you experience severe bone, joint, or muscle pain. · Avoid lying down for at least 60 minutes after taking oral ibandronate. |